Type 2 diabetes management has been transformed by remarkable therapeutic advances. Today's tools — continuous glucose monitors, GLP-1 medications, SGLT2 inhibitors — make excellent glucose control achievable for most patients, often with the added benefits of weight loss and cardiovascular protection.
Understanding Type 2 Diabetes
Type 2 diabetes is characterized by insulin resistance (cells don't respond normally to insulin) combined with progressive loss of insulin secretion by pancreatic beta cells. Unlike type 1, type 2 diabetes is strongly influenced by lifestyle factors — obesity, physical inactivity, and diet — though genetic predisposition plays a significant role.
Monitoring Tools: Know Your Numbers
HbA1c (Glycated Hemoglobin)
The HbA1c reflects average blood glucose over the prior 2-3 months. Target for most patients: <7.0%. More aggressive targets (<6.5%) may be appropriate for younger patients with recent diagnosis; less aggressive targets (<8.0%) for elderly patients or those with frequent hypoglycemia.
Continuous Glucose Monitoring (CGM)
CGM devices (Dexcom G7, Libre 3) provide real-time glucose readings every 1-5 minutes with trend arrows, high/low alerts, and downloadable data. CGM use is associated with 0.5-1.0% improvement in HbA1c and dramatic reduction in hypoglycemic events. I prescribe CGM for virtually all my insulin-using patients and many non-insulin users as well.
The Pillars of Diabetes Treatment
1. Lifestyle Modification
- Mediterranean or low-glycemic index diet (not "no carbs" — complex carbs with fiber are fine)
- 150+ minutes of moderate aerobic exercise per week
- Resistance training 2-3 days/week (improves insulin sensitivity significantly)
- Weight loss of 5-10% in overweight/obese patients dramatically improves glucose control
2. Metformin — Still the Foundation
Metformin remains first-line therapy for type 2 diabetes. Inexpensive, effective, weight-neutral or slightly weight-reducing, and has a proven cardiovascular safety record over 60 years. Extended-release formulation reduces GI side effects.
3. GLP-1 Receptor Agonists
Semaglutide (Ozempic) and tirzepatide (Mounjaro) are transformative medications that lower A1C by 1.5-2+%, promote 10-22% weight loss, and provide cardiovascular protection. They are now second-line or even first-line in patients with cardiovascular disease or obesity.
4. SGLT2 Inhibitors
Empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana) lower glucose by causing kidneys to excrete excess sugar. Additional benefits: weight loss, blood pressure reduction, heart failure prevention, and slowing of chronic kidney disease progression. Now considered first-line in patients with heart failure or CKD.
5. Insulin
Not a treatment failure — for many patients, insulin is the most effective tool available. Modern basal insulins (degludec, glargine U-300) provide excellent glucose control with low hypoglycemia risk. When added to oral medications, basal insulin often achieves excellent control.
Preventing Diabetes Complications
The UKPDS, DCCT/EDIC, and ACCORD trials established that excellent glucose control prevents microvascular complications. Every 1% reduction in HbA1c reduces risk of diabetic kidney disease by 37%, diabetic eye disease by 37%, and nerve damage by 39%.
Our diabetes monitoring protocol includes: quarterly A1C, annual kidney function and urine albumin, annual eye exam referral, annual foot exam, and blood pressure and lipid management.